Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH)
Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH): a Multi-center Randomized, Controlled, Assessor-blinded Trial
Sponsor: Xijing Hospital
Listed as NCT03741530, this NA trial focuses on Intracerebral Hemorrhage and remains completed. Sponsored by Xijing Hospital, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
May 2022 — Jul 2024 [monthly]
Completed NA
-
Dec 2021 — May 2022 [monthly]
Completed NA
-
May 2021 — Dec 2021 [monthly]
Completed NA
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting NA
-
Aug 2020 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2020 — Aug 2020 [monthly]
Recruiting NA
-
May 2019 — Feb 2020 [monthly]
Recruiting NA
Status: Enrolling By Invitation → Recruiting
-
Jan 2019 — May 2019 [monthly]
Enrolling By Invitation NA
-
Dec 2018 — Jan 2019 [monthly]
Enrolling By Invitation NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Xijing Hospital
For direct contact, visit the study record on ClinicalTrials.gov .